[{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"RBP4","sponsor":"Belite Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Undisclosed","graph2":"Phase I","graph3":"RBP4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RBP4 \/ Belite Bio","highestDevelopmentStatusID":"6","companyTruncated":"RBP4 \/ Belite Bio"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Benchmark Company"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ The Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ The Benchmark Company"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ SVB Securities"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Belite Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.28000000000000003,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ RA Capital Management"},{"orgOrder":0,"company":"RBP4","sponsor":"Belite Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"RBP4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RBP4 \/ Belite Bio","highestDevelopmentStatusID":"7","companyTruncated":"RBP4 \/ Belite Bio"},{"orgOrder":0,"company":"RBP4","sponsor":"Belite Bio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase I","graph3":"RBP4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RBP4 \/ Belite Bio","highestDevelopmentStatusID":"6","companyTruncated":"RBP4 \/ Belite Bio"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Morgan Stanley | Leerink Partners | BofA Securities | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Morgan Stanley | Leerink Partners | BofA Securities | Cantor","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Morgan Stanley | Leerink Partners | BofA Securities | Cantor"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Tinlarebant
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
